Yu J C, Sung R J
Falk Cardiovascular Research Center, Stanford University Medical Center, California, USA.
Cardiovasc Drugs Ther. 1997 Jan;10(6):687-92. doi: 10.1007/BF00053025.
The pharmacological response with tilt-table testing predicts long-term efficacy in neurocardiogenic syncope. However, beta-blockers for neurocardiogenic syncope are often not tolerated or are ineffective. Since cholinergic tone is important in the efferent part of the neurocardiogenic reflex, we investigated the pharmacodynamics and efficacy of propantheline bromide in preventing neurocardiogenic syncope. We studied 16 patients (11 males) with a mean age of 48.8 (+/- 15.1) years with presyncope or syncope and who had positive baseline tilt-table studies at a mean of 15.8 (+/- 10.3) minutes into the upright 60 degrees tilt. They were given propantheline bromide orally, an anticholinergic agent, at a dose of 64.3 (+/- 21.8) mg/day for 7 days, and tilt-table testing was repeated 1 hour after readministration of propantheline bromide, 30 mg orally. After propantheline bromide treatment, 13 of 16 patients (81%) had no inducible presyncope or syncope on repeat tilt-table testing. In this group of responders, the mean minimum heart rate during upright tilt-table testing increased from 43.2 (+/- 77.3) beats/min to 77.3 (+/- 17.2) beats/min after propantheline bromide (p < 0.005). More significantly, the minimum mean arterial blood pressure increased from 42.2 (+/- 25) mmHg to 81.3 (+/- 16.7) mmHg (p < 0.0005) during upright tilt. At a follow-up of 15.2 (+/- 7.4) months, in the responder group (12 patients with long-term follow-up), the average dose of propantheline bromide was 32.5 (+/- 23.8) mg/day, which was significantly reduced from the initial dose (p < 0.05). A clinical recurrence of symptoms occurred in only 4 out of 12 patients on propantheline bromide (33%), none of which were directly attributable to drug failure. It was concluded from this study that propantheline bromide is highly effective in preventing neurocardiogenic syncope. In addition, propantheline bromide's effectiveness is more than would be expected by prevention of cardioinhibition in neurocardiogenic syncope and would support a role for direct cholinergic control of vascular tone.
倾斜试验的药理学反应可预测神经心源性晕厥的长期疗效。然而,用于神经心源性晕厥的β受体阻滞剂常常无法耐受或无效。由于胆碱能张力在神经心源性反射的传出部分起重要作用,我们研究了溴丙胺太林预防神经心源性晕厥的药效学及疗效。我们研究了16例患者(11例男性),平均年龄48.8(±15.1)岁,有晕厥前症状或晕厥,且在直立60度倾斜平均15.8(±10.3)分钟时基础倾斜试验呈阳性。给予他们口服抗胆碱能药物溴丙胺太林,剂量为64.3(±21.8)mg/天,共7天,再次口服30 mg溴丙胺太林1小时后重复倾斜试验。溴丙胺太林治疗后,16例患者中有13例(81%)在重复倾斜试验时未诱发晕厥前症状或晕厥。在这组有反应者中,直立倾斜试验期间的平均最低心率从43.2(±77.3)次/分钟增加到溴丙胺太林治疗后的77.3(±17.2)次/分钟(p<0.005)。更显著的是,直立倾斜期间平均最低动脉血压从42.2(±25)mmHg增加到81.3(±16.7)mmHg(p<0.0005)。在15.2(±7.4)个月的随访中,在有反应者组(12例有长期随访)中,溴丙胺太林的平均剂量为32.5(±23.8)mg/天,较初始剂量显著降低(p<0.05)。服用溴丙胺太林的12例患者中仅4例(33%)出现症状临床复发,且均与药物失效无直接关系。该研究得出结论,溴丙胺太林在预防神经心源性晕厥方面非常有效。此外,溴丙胺太林的有效性超过了通过预防神经心源性晕厥中的心脏抑制所预期的效果,这支持直接胆碱能控制血管张力的作用。